Heilongjiang University of Chinese Medicine, Harbin, China.
Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Phytother Res. 2024 Jun;38(6):2892-2930. doi: 10.1002/ptr.8203. Epub 2024 Apr 5.
Atherosclerotic cardiovascular disease remains a preeminent cause of morbidity and mortality globally. The onset of atherosclerosis underpins the emergence of ischemic cardiovascular diseases, including coronary heart disease (CHD). Its pathogenesis entails multiple factors such as inflammation, oxidative stress, apoptosis, vascular endothelial damage, foam cell formation, and platelet activation. Furthermore, it triggers the activation of diverse signaling pathways including Phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), NF-E2-related factor 2/antioxidant response element (Nrf2/ARE), the Notch signaling pathway, peroxisome proliferator-activated receptor (PPAR), nucleotide oligo-structural domain-like receptor thermoprotein structural domain-associated protein 3 (NLRP3), silencing information regulator 2-associated enzyme 1 (Sirt1), nuclear transcription factor-κB (NF-κB), Circular RNA (Circ RNA), MicroRNA (mi RNA), Transforming growth factor-β (TGF-β), and Janus kinase-signal transducer and activator of transcription (JAK/STAT). Over recent decades, therapeutic approaches for atherosclerosis have been dominated by the utilization of high-intensity statins to reduce lipid levels, despite significant adverse effects. Consequently, there is a growing interest in the development of safer and more efficacious drugs and therapeutic modalities. Traditional Chinese medicine (TCM) offers a vital strategy for the prevention and treatment of cardiovascular diseases. Numerous studies have detailed the mechanisms through which TCM active ingredients modulate signaling molecules and influence the atherosclerotic process. This article reviews the signaling pathways implicated in the pathogenesis of atherosclerosis and the advancements in research on TCM extracts for prevention and treatment, drawing on original articles from various databases including Google Scholar, Medline, CNKI, Scopus, and Pubmed. The objective is to furnish a reference for the clinical management of cardiovascular diseases.
动脉粥样硬化性心血管疾病仍然是全球发病率和死亡率的主要原因。动脉粥样硬化的发生是缺血性心血管疾病(包括冠心病)出现的基础。其发病机制涉及多种因素,如炎症、氧化应激、细胞凋亡、血管内皮损伤、泡沫细胞形成和血小板激活。此外,它还触发了多种信号通路的激活,包括磷脂酰肌醇 3-激酶/蛋白激酶 B(PI3K/Akt)、核因子 E2 相关因子 2/抗氧化反应元件(Nrf2/ARE)、Notch 信号通路、过氧化物酶体增殖物激活受体(PPAR)、核苷酸寡结构域样受体热蛋白结构域相关蛋白 3(NLRP3)、沉默信息调节因子 2 相关酶 1(Sirt1)、核转录因子-κB(NF-κB)、Circ RNA、MicroRNA(miRNA)、转化生长因子-β(TGF-β)和 Janus 激酶-信号转导和转录激活因子(JAK/STAT)。近几十年来,尽管存在显著的不良反应,但治疗动脉粥样硬化的方法主要是利用高强度他汀类药物来降低血脂水平。因此,人们越来越关注开发更安全、更有效的药物和治疗方式。中药(TCM)为心血管疾病的防治提供了重要策略。许多研究详细说明了 TCM 活性成分调节信号分子和影响动脉粥样硬化过程的机制。本文综述了与动脉粥样硬化发病机制相关的信号通路以及 TCM 提取物在预防和治疗方面的研究进展,参考了来自 Google Scholar、Medline、CNKI、Scopus 和 Pubmed 等多个数据库的原始文章。目的是为心血管疾病的临床管理提供参考。